Case Studies

2024-11-05

Antibody Fragment Production

Using AtaGenix's mammalian cell expression system, various antibody fragments have been successfully expressed, including scFv, VHH, Fab, and scFv-Fc-scFv, meeting diverse research and development needs.The accompanying images demonstrate the expression results and workflow of antibody production using this advanced system.

2024-11-05

Stable Cell Lines

CHO stable cell lines were developed for recombinant antibody production, achieving over 3 g/L expression. Analyses of yield, stability, mycoplasma, purity, and affinity confirmed antibody quality. Additionally, a stable line for Varicella-Zoster Virus gE protein was validated, demonstrating biopharmaceutical versatility

2024-11-05

Large-Scale Recombinant Antibody Production

Using AtaGenix's proprietary XtenCHO™ mammalian expression system, full-length IgG, VHH, scFv, and Fab antibody fragments were successfully expressed. The accompanying SDS-PAGE analysis demonstrates the system's ability to produce high-quality proteins:

2024-11-05

Chimeric Antibody Production

Chimeric antibody production combines the variable region of one species with the constant region of another to achieve optimal specificity and functionality. This approach ensures high binding affinity while maintaining robust stability and compatibility with downstream applications. Utilizing cutting-edge expression systems, production is scalable, cost-effective, and delivers high-purity antibodies suitable for therapeutic and research purposes.

2024-11-05

Bispecific Antibody Development

This case study showcases the quality and functionality assessment of Dubody bispecific antibodies through QC, SEC-HPLC monomer purity, and ELISA titer analysis. The results confirm high purity and robust activity, supporting their application in therapeutic development.

2024-11-05

Bacillus subtilis

Two case studies highlight Bacillus subtilis as an efficient host for recombinant protein production. Protein A (20 mg/L, >90% purity) and Protein B (1 mg/L, >95% purity) demonstrate its scalability and reliability.

2024-11-05

Preparation of MHC-Peptide Complex Proteins

HLA-I protein and β2M were expressed and purified in E. coli, followed by refolding to form stable HLA/β2M/peptide complexes (pMHC). The addition of streptavidin (SA) enabled the formation of stable tetramers for downstream applications.

2024-11-05

E. coli Expression System

This study demonstrates the optimization of E. coli expression systems for recombinant protein and antibody fragment production. Strategies included host strain selection, periplasmic expression for proper folding, and refolding inclusion bodies into active soluble proteins. Results showcase high-quality protein expression and QC validation.

2024-11-05

Hybridoma Sequencing

Hybridoma sequencing enables the precise identification of heavy and light chain variable regions of monoclonal antibodies. The data includes high-quality PCR amplification, colony validation gels, and sequencing results, ensuring accuracy in gene identification and antibody production.

2024-11-04

Insect-Baculovirus Expression System Case Study

This case study demonstrates the use of the insect-baculovirus expression system for efficient production of recombinant proteins. The approach achieved high yields with proper folding and post-translational modifications, showcasing its reliability for complex protein expression.

2024-11-04

Xten™ Mab Single B Rabbit Monoclonal Antibody Development Case Study

Using rabbit single B-cell antibody technology, an Anti-human CD86 rabbit monoclonal antibody was developed. Rabbits with serum titers greater than 128K were selected, and PBMCs were isolated for flow sorting to obtain human CD86 antigen-specific B-cell plates.

2024-11-04

Mammalian HEK293 Expression

The results show that the SARS-CoV-2 S protein expressed in mammalian cells achieved high yields during purification, with clear target protein bands observed in elution fractions (E1-E8) and minimal impurities.